285 related articles for article (PubMed ID: 28721884)
1. Dosimetric Predictors of Patient-Reported Xerostomia and Dysphagia With Deintensified Chemoradiation Therapy for HPV-Associated Oropharyngeal Squamous Cell Carcinoma.
Chera BS; Fried D; Price A; Amdur RJ; Mendenhall W; Lu C; Das S; Sheets N; Marks L; Mavroidis P
Int J Radiat Oncol Biol Phys; 2017 Aug; 98(5):1022-1027. PubMed ID: 28721884
[TBL] [Abstract][Full Text] [Related]
2. Dose-volume toxicity modeling for de-intensified chemo-radiation therapy for HPV-positive oropharynx cancer.
Mavroidis P; Price A; Fried D; Kostich M; Amdur R; Mendenhall W; Liu C; Das S; Marks LB; Chera B
Radiother Oncol; 2017 Aug; 124(2):240-247. PubMed ID: 28712533
[TBL] [Abstract][Full Text] [Related]
3. Phase 2 Trial of De-intensified Chemoradiation Therapy for Favorable-Risk Human Papillomavirus-Associated Oropharyngeal Squamous Cell Carcinoma.
Chera BS; Amdur RJ; Tepper J; Qaqish B; Green R; Aumer SL; Hayes N; Weiss J; Grilley-Olson J; Zanation A; Hackman T; Funkhouser W; Sheets N; Weissler M; Mendenhall W
Int J Radiat Oncol Biol Phys; 2015 Dec; 93(5):976-85. PubMed ID: 26581135
[TBL] [Abstract][Full Text] [Related]
4. Comparison of Patient- and Practitioner-Reported Toxic Effects Associated With Chemoradiotherapy for Head and Neck Cancer.
Falchook AD; Green R; Knowles ME; Amdur RJ; Mendenhall W; Hayes DN; Grilley-Olson JE; Weiss J; Reeve BB; Mitchell SA; Basch EM; Chera BS
JAMA Otolaryngol Head Neck Surg; 2016 Jun; 142(6):517-23. PubMed ID: 27149571
[TBL] [Abstract][Full Text] [Related]
5. Contribution of submandibular gland and swallowing structure sparing to post-radiation therapy PEG dependence in oropharynx cancer patients treated with split-neck IMRT technique.
Gensheimer MF; Nyflot M; Laramore GE; Liao JJ; Parvathaneni U
Radiat Oncol; 2016 Nov; 11(1):151. PubMed ID: 27846899
[TBL] [Abstract][Full Text] [Related]
6. Comparison of xerostomia incidence after three-dimensional conformal radiation therapy and contralateral superficial lobe parotid-sparing intensity-modulated radiotherapy for oropharyngeal and hypopharyngeal cancer.
Kawamoto T; Nihei K; Nakajima Y; Kito S; Sasai K; Karasawa K
Auris Nasus Larynx; 2018 Oct; 45(5):1073-1079. PubMed ID: 29397249
[TBL] [Abstract][Full Text] [Related]
7. NTCP modelling of xerostomia after radiotherapy for oropharyngeal cancer using the PRO-CTCAE and CTCAE scoring systems at different time-points post-RT.
Tzikas A; Lavdas E; Kehagias D; Amdur R; Mendenhall W; Sheets N; Green R; Chera B; Mavroidis P
Phys Med; 2023 Dec; 116():103169. PubMed ID: 37989042
[TBL] [Abstract][Full Text] [Related]
8. Using a reduced spot size for intensity-modulated proton therapy potentially improves salivary gland-sparing in oropharyngeal cancer.
van de Water TA; Lomax AJ; Bijl HP; Schilstra C; Hug EB; Langendijk JA
Int J Radiat Oncol Biol Phys; 2012 Feb; 82(2):e313-9. PubMed ID: 21708427
[TBL] [Abstract][Full Text] [Related]
9. Sparing bilateral neck level IB in oropharyngeal carcinoma and xerostomia outcomes.
Tam M; Riaz N; Kannarunimit D; Peña AP; Schupak KD; Gelblum DY; Wolden SL; Rao S; Lee NY
Am J Clin Oncol; 2015 Aug; 38(4):343-7. PubMed ID: 26208401
[TBL] [Abstract][Full Text] [Related]
10. Chemo-IMRT of oropharyngeal cancer aiming to reduce dysphagia: swallowing organs late complication probabilities and dosimetric correlates.
Eisbruch A; Kim HM; Feng FY; Lyden TH; Haxer MJ; Feng M; Worden FP; Bradford CR; Prince ME; Moyer JS; Wolf GT; Chepeha DB; Ten Haken RK
Int J Radiat Oncol Biol Phys; 2011 Nov; 81(3):e93-9. PubMed ID: 21592678
[TBL] [Abstract][Full Text] [Related]
11. Mature results of a prospective study of deintensified chemoradiotherapy for low-risk human papillomavirus-associated oropharyngeal squamous cell carcinoma.
Chera BS; Amdur RJ; Tepper JE; Tan X; Weiss J; Grilley-Olson JE; Hayes DN; Zanation A; Hackman TG; Patel S; Sheets N; Weissler MC; Mendenhall WM
Cancer; 2018 Jun; 124(11):2347-2354. PubMed ID: 29579339
[TBL] [Abstract][Full Text] [Related]
12. Long-term follow-up of protective effects on salivary and swallowing structures and improvement of late xerostomia and dysphagia by level IIb optimisation in clinical target volume of nasopharyngeal carcinoma.
Zhou J; Wang L; Qiu T; Gao H; Wang L; Huang S; He X; Wu L
BMC Cancer; 2024 May; 24(1):648. PubMed ID: 38802747
[TBL] [Abstract][Full Text] [Related]
13. Long-term quality of life after swallowing and salivary-sparing chemo-intensity modulated radiation therapy in survivors of human papillomavirus-related oropharyngeal cancer.
Vainshtein JM; Moon DH; Feng FY; Chepeha DB; Eisbruch A; Stenmark MH
Int J Radiat Oncol Biol Phys; 2015 Apr; 91(5):925-33. PubMed ID: 25832685
[TBL] [Abstract][Full Text] [Related]
14. Radiation-Associated Chronic Dysphagia Assessment by Flexible Endoscopic Evaluation of Swallowing (FEES) in Head and Neck Cancer Patients: Swallowing-Related Structures and Radiation Dose-Volume Effect.
Ozkaya Akagunduz O; Eyigor S; Kirakli E; Tavlayan E; Erdogan Cetin Z; Kara G; Esassolak M
Ann Otol Rhinol Laryngol; 2019 Feb; 128(2):73-84. PubMed ID: 30343589
[TBL] [Abstract][Full Text] [Related]
15. Influence of radiation dose to pharyngeal constrictor muscles on late dysphagia and quality of life in patients with locally advanced oropharyngeal carcinoma.
Mogadas S; Busch CJ; Pflug C; Hanken H; Krüll A; Petersen C; Tribius S
Strahlenther Onkol; 2020 Jun; 196(6):522-529. PubMed ID: 32006068
[TBL] [Abstract][Full Text] [Related]
16. Predicting acute radiation induced xerostomia in head and neck Cancer using MR and CT Radiomics of parotid and submandibular glands.
Sheikh K; Lee SH; Cheng Z; Lakshminarayanan P; Peng L; Han P; McNutt TR; Quon H; Lee J
Radiat Oncol; 2019 Jul; 14(1):131. PubMed ID: 31358029
[TBL] [Abstract][Full Text] [Related]
17. Reducing xerostomia after chemo-IMRT for head-and-neck cancer: beyond sparing the parotid glands.
Little M; Schipper M; Feng FY; Vineberg K; Cornwall C; Murdoch-Kinch CA; Eisbruch A
Int J Radiat Oncol Biol Phys; 2012 Jul; 83(3):1007-14. PubMed ID: 22056067
[TBL] [Abstract][Full Text] [Related]
18. Functional Outcomes After De-escalated Chemoradiation Therapy for Human Papillomavirus-Positive Oropharyngeal Cancer: Secondary Analysis of a Phase 2 Trial.
Hegde JV; Shaverdian N; Felix C; Wang PC; Veruttipong D; Hsu S; Riess JW; Rao SD; Daly ME; Chen AM
Int J Radiat Oncol Biol Phys; 2018 Mar; 100(3):647-651. PubMed ID: 29246721
[TBL] [Abstract][Full Text] [Related]
19. Assessment of gene expressions from squamous cell carcinoma of the head and neck to predict radiochemotherapy-related xerostomia and dysphagia.
Yahya N; Linge A; Leger K; Maile T; Kemper M; Haim D; Jöhrens K; Troost EGC; Krause M; Löck S
Acta Oncol; 2022 Jul; 61(7):856-863. PubMed ID: 35657056
[TBL] [Abstract][Full Text] [Related]
20. A phase II study to assess the efficacy of amifostine for submandibular/sublingual salivary sparing during the treatment of head and neck cancer with intensity modulated radiation therapy for parotid salivary sparing.
Rosenthal DI; Chambers MS; Weber RS; Eisbruch A
Semin Oncol; 2004 Dec; 31(6 Suppl 18):25-8. PubMed ID: 15726519
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
